Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 358Carcinoma, Non-Small-Cell Lung 178Neoplasms 109Breast Neoplasms 97Lung Neoplasms 81Urinary Bladder Neoplasms 79Neoplasm Metastasis 74Ovarian Neoplasms 53Cholangiocarcinoma 39Sarcoma 38Lymphoma 38Biliary Tract Neoplasms 35Gallbladder Neoplasms 34Hodgkin Disease 30Lymphoma, Non-Hodgkin 27Adenocarcinoma 27Lymphoma, Large B-Cell, Diffuse 25Colorectal Neoplasms 24Bile Duct Neoplasms 23Triple Negative Breast Neoplasms 22Recurrence 22Fallopian Tube Neoplasms 22Unspecified Adult Solid Tumor, Protocol Specific 21Carcinoma, Transitional Cell 21Carcinoma, Ovarian Epithelial 21Urethral Neoplasms 20Carcinoma 17Adenocarcinoma of Lung 15Head and Neck Neoplasms 14Carcinoma, Renal Cell 14

Interventions

pembrolizumab 1paricalcitol 1Taxes 1Gemcitabine 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Resectable Pancreatic Carcinoma × Gemcitabine × Clear all
NCT02930902 2023-02-09

Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery

M.D. Anderson Cancer Center

Phase 1 Completed
9 enrolled
Gastrointestinal

Resectable Pancreatic Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡